tag:blogger.com,1999:blog-7857054149675424609.post8282207218160098762..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: Clinical Experience with RNAi Therapeutics Suggests Class to be Remarkably SafeDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-7857054149675424609.post-15488999580497017212011-03-01T10:00:44.930+00:002011-03-01T10:00:44.930+00:00I'm not clear what type of cell death you are ...I'm not clear what type of cell death you are referring to. For some formulations and at low pH as may be encountered in some solid tumors, non-RNAi membrane damage may indeed contribute selectively to tumor cell death whereas the same formulation is innocuous in the rest of the body.Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-23503792352861959402011-03-01T02:24:21.236+00:002011-03-01T02:24:21.236+00:00Hi Dirk,
Glad you are posting again. Can you spea...Hi Dirk,<br />Glad you are posting again. Can you speak to cell death as a result of delivering rna intracellulary. What's the preclinical data telling you. If this is a possible risk it would make sense why cancer would be a good target for early development. Would we then be trying to compare binding between rnai molecules with small moleculess and antibodies?Anonymousnoreply@blogger.com